Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial
1. 系统已在2026-06-16 14:35:22对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
S Al Said, SM Patel, RP Giugliano, DA Morrow…
JAMA …, 2026
jamanetwork.com
Importance Older age is a strong risk factor for bleeding with currently available anticoagulants. Factor XI (FXI) inhibition may offer a safer anticoagulant strategy in this population. Objective To evaluate the safety of the novel FXI inhibitor abelacimab vs rivaroxaban by age in patients with atrial fibrillation (AF). Design, Setting, and Participants The randomized clinical trial AZALEA-TIMI 71 randomized patients with AF to receive 1 of 2 subcutaneous abelacimab doses (90 mg or 150 mg monthly) or oral rivaroxaban (20 mg …
